T. Rowe Price Investment Management Inc. Sells 267,668 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

T. Rowe Price Investment Management Inc. trimmed its holdings in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 2.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,466,721 shares of the company's stock after selling 267,668 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 18.50% of Black Diamond Therapeutics worth $22,399,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Intech Investment Management LLC increased its position in shares of Black Diamond Therapeutics by 49.1% during the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock valued at $41,000 after purchasing an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock worth $41,000 after purchasing an additional 15,355 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Black Diamond Therapeutics during the fourth quarter valued at about $42,000. Wells Fargo & Company MN boosted its position in Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock valued at $43,000 after buying an additional 5,932 shares during the period. Finally, Sei Investments Co. bought a new stake in Black Diamond Therapeutics in the 4th quarter worth $49,000. Institutional investors own 95.47% of the company's stock.

Insider Activity at Black Diamond Therapeutics

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares in the company, valued at $5,658,442.29. This trade represents a 67.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.87% of the stock is currently owned by corporate insiders.

Black Diamond Therapeutics Price Performance

Shares of NASDAQ BDTX traded up $0.05 during mid-day trading on Friday, hitting $1.75. The company had a trading volume of 659,553 shares, compared to its average volume of 1,472,764. Black Diamond Therapeutics, Inc. has a 12 month low of $1.20 and a 12 month high of $7.66. The stock has a market cap of $98.90 million, a price-to-earnings ratio of -1.31 and a beta of 2.81. The firm's 50 day simple moving average is $1.63 and its two-hundred day simple moving average is $2.23.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. Equities analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BDTX. HC Wainwright lifted their target price on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Stifel Nicolaus decreased their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Finally, Wedbush reissued an "outperform" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, March 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Black Diamond Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $14.60.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.